Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13523858 | 0.85 | MAOB (0.52) | MAOBALOX5MTNR1A | |
| SCHEMBL13523859 | 0.85 | MAOB (0.52) | MAOBALOX5MTNR1A | |
| SCHEMBL13523863 | 0.81 | MAOB (0.49) | MAOBALOX5MTNR1A | |
| SCHEMBL13523864 | 0.81 | MTNR1A (0.74) | MTNR1A | |
| SCHEMBL6375516 | 0.80 | ADRA1A (0.65) | ADRA1ATAAR1MTNR1A | |
| SCHEMBL6382816 | 0.78 | ADRA1A (0.65) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL13523861 | 0.76 | MAOB (0.58) | MAOBALOX5 | |
| SCHEMBL13523860 | 0.76 | MAOB (0.51) | MAOBALOX5 | |
| SCHEMBL20562784 | 0.75 | TAAR1 (0.51) | TRPM8MAPTADRA1ATAAR1 | |
| SCHEMBL29594789 | 0.74 | HTR2A (0.68) | MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004340-A1 | NAPHTHYL(ETHYL) ACETAMIDES | CONCERT PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004340-A1 | NAPHTHYL(ETHYL) ACETAMIDES | CONCERT PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-7608737-B2 | Naphthyl(ethyl)acetamides | Concert Pharmaceuticasl Inc. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608737-B2 | Naphthyl(ethyl)acetamides | Concert Pharmaceuticasl Inc. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080280908-A1 | NAPHTHYL(ETHYL) ACETAMIDES | CONCERT PHARMACEUTICALS INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280908-A1 | NAPHTHYL(ETHYL) ACETAMIDES | CONCERT PHARMACEUTICALS INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008137461-A1 | NAPHTHYL(ETHYL) ACETAMIDES | CONCERT PHARMACEUTICALS INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280908-A1 | NAPHTHYL(ETHYL) ACETAMIDES | AANAT, MTNR1A, TPH2 | TRPM8 472/4885KDM4E 3270/4885MAPT 836/4885 |
| US-20100004340-A1 | NAPHTHYL(ETHYL) ACETAMIDES | AANAT, MTNR1A, TPH2 | TRPM8 472/4885KDM4E 3270/4885MAPT 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.